Average Co-Inventor Count = 12.12
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Abbvie Inc. (20 from 822 patents)
2. Abbott Laboratories Corporation (8 from 4,179 patents)
3. Genentech, Inc. (2 from 3,222 patents)
4. Walter and Eliza Hall Institute of Medical Research (2 from 80 patents)
5. Abbvie Bahamas Limited (6 patents)
28 patents:
1. 11897864 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
2. 10035800 - Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
3. 9321764 - Dihydro-pyrrolopyridinone inhibitors
4. 9303025 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
5. 9296741 - Bromodomain inhibitors
6. 9174982 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
7. 9125913 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
8. 9073855 - BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases
9. 9072748 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
10. 9051315 - Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
11. 9045420 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
12. 9034875 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
13. 9029404 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
14. 8586754 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
15. 8580794 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases